A Comparative Study of the Inclusion Complexes of 2-[5’-benzylidene-2’-phenyl-4’-oxo-1’, 3’-thiazolidine]-1, 3-benzothiazole and 2-[5’-(p-N,N-dimethylamino-benzylidene)-2’-phenyl-4’-oxo-1’, 3’-thiazolidine]-1, 3-benzothiazole with β-Cyclodextrin

S. PANDA* and S.K.DASH

P. G. Department of Chemistry, Berhampur University, Bhanjabinhar, Berhampur-760007, Ganjam, Odisha, India
sunakar_bu@yahoo.co.in

Received 4 September 2010; Accepted 6 November 2010

Abstract: The compounds 2-[5’-benzylidene-2’-phenyl-4’-oxo-1’,3’-thiazolidine]-1,3-benzothiazole and 2-[5’-(p-N,N-dimethylaminobenzylidene)-2’-phenyl-4’-oxo-1’,3’-thiazolidine]-1,3-benzothiazole have been synthesized in their purest forms starting from 2-aminobenzothiazole. The inclusion complexes of the above compounds have been prepared with β-cyclodextrin to increase their solubility and bioaccessibility in polar medium. The formation of inclusion complexes have been ascertained by study of spectral characteristic before and after inclusion complex formation. The stability of inclusion complexes and nature of interaction between the host and guest are known from the determination of thermodynamic parameters. Further the antibacterial and antifungal activities of the compounds are determined which is found to increase significantly after inclusion complex formation

Keywords: 2-Aminobenzothiazole, Inclusion complex, β-Cyclodextrin, Antimicrobial activity.

Introduction

The derivatives of benzothiazole exhibit a wide spectrum of pharmacological activities such as antitubercular1, antimicrobial2, antifugicidal3-5 and antiallergic6. The amino of (-NH₂) group of 2-aminobenzothiazole can be used as a very good target for condensing with 2-oxo-azetidine and their 5-benzylidene moieties generating a series of 2-[5’-(aryldene)-2’-p-substituted phenyl-4’-oxo-1’,3’-thiazolidine]-1,3-benzothiazole which have significant antimicrobial activities7-16. These compounds being insoluble in polar medium may have poor pharmacological activities17. The solubility of these compounds can be enhanced by forming inclusion (host-guest) complexes with β-cyclodextrins (β-CD) which in turn increase their solubility and drug efficiency18.
In the present work, an attempt has been made to synthesize 2-[5'-benzylidene-2'-phenyl-4'-oxo-1', 3'-thiazolidine]-1, 3-benzothiazole(IIIA) and 2-[5'-(p-N,N-dimethylamino-benzylidene)-2'-phenyl-4'-oxo-1',3'-thiazolidine]-1,3-benzothiazole(IIIB) and to prepare their inclusion complexes with β-CD. The formation of compounds and their inclusion complexes have been ascertained by the study of spectral characteristics. Thermodynamic parameters of the inclusion complexes have been calculated to have an idea about the stability of the compounds with in β-CD cavity. Finally antibacterial and antifungal activities of the compounds have been determined to examine whether the inclusion complex formation is enhancing the bioaccessibility of the compounds or not.

**Experimental**

The elemental analysis of the compounds synthesized has been performed in a CHN analyzer. Electronic spectra are recorded on Shimadzu UV-1700 spectrophotometers while IR spectra are recorded in KBr pallets in the range of 400-4000 cm$^{-1}$ region in a Shimadzu 8400 S FTIR spectrophotometer. Melting points are recorded by open capillary method.

The pure compounds have been synthesized as per the method described by Srivastava et al.$^{33}$ Equimolar solution of 2-aminobenzothiazole (5 g, 0.03 mol) and benzaldehyde (3.38 mL, 0.03 mol) with few drops of glacial acetic acid in MeOH (50 mL) was refluxed on water with bath for about 1 h. The solvent was removed in vacuo and the residue was purified over the column of silica gel using CHCl$_3$. The product was recrystallized from ethanol to give 2-N-(benzyledine)-imino-1, 3-benzothiazole(I).

A mixture of the compound I (3 g, 0.01 mL) and thioglycolic acid (0.91 mL, 0.01 mol) in the presence of ZnCl$_2$ in benzene (50 mL) is refluxed on a water bath for about 15 h. The solvent was removed in vacuo and the residue was purified over the column of silica gel using CHCl$_3$ as an eluent. The product was recrystallized from ethanol to afford compound 2-[2'-(phenyl)-4'-oxo-1', 3'-thiazolidine]-1, 3-benzothiazole(II).

Equimolar solution of the compound II (2 g, 0.006 mol) and benzaldehyde (0.65 mL, 0.006 mol) in dioxane (20 mL) in the presence of C$_2$H$_5$OK was refluxed on a water bath for about 6 h. The solvent was removed in vacuo and the residue was purified over the column of silica gel using CHCl$_3$ as an eluent. The product was recrystallized from ethanol to yield compound 2-[5'-benzylidene-2'-phenyl-4'-oxo-1',3'-thiazolidine]-1,3-benzothiazole(IIIA). Similarly the compound IIIB was synthesized as per the procedure given above using p-N,N-dimethylaminobenzaldehyde in place of benzaldehyde. The synthesis of compound IIIA and IIIB are shown in Scheme 1.

![Scheme 1](image-url)

The aqueous phase solubility of compound IIIA and IIIB at various concentration of β-CD have been studied by Higuchi Connors method.$^{19}$ Accurately weighed sample of these
compounds in quantities exceeding their aqueous solubility were shaken in a rotary flash shaker at room temperature with aqueous solution of β-CD in increasing concentration in a series of stoppered conical flasks for a period of 48 h till equilibrium is established.

The solutions were filtered through Whatman No 1 paper and were analysed in a UV-Vis spectrophotometer at 200-400 nm range. The various values of OD at λ_max have been plotted against different concentration of β-CD. The inclusion complexes of compounds IIIA and IIIB have been prepared as per Nayak et al. The solutions of the synthesized compound were prepared in required concentration (0.05 mM) and were added drop wise to previously stirred β–CD solution. The mixture were stirred at room temperature for 48 h and filtered. Then the contents are cooled for another 48 h in refrigerator. Finally the precipitate obtained are filtered through G-4 crucible, washed with double distilled water and dried in air for 24 h.

The thermodynamic stability constant (K_T) at room temperature of the inclusion complexes have been calculated using Benesi-Hilderbrand relation. The stability constant K (during deencapsulation) of the complexes are calculated with increasing temperature. The slope of the linear plot of ln K against 1/T gives rise to the calculation of ΔH (change in enthalpy) and then ΔS (change in entropy) was calculated using the integrated form of the van’t-Hoff equation.

\[
\ln K = (-\Delta H/RT) + \Delta S/R
\]

The value of ΔG was calculated from the value of K_T at 298 K using the equation

\[
\Delta G = -RT \ln K_T
\]

The antibacterial and antifungal properties of compounds (IIIA and IIIB) and their inclusion complexes with β-CD have been studied as per Cappuccino and Cooper respectively.

Results and Discussion

The synthesis of compound IIIA and IIIB have been confirmed from elemental analysis and IR data as shown in the Table 1. The elemental composition nearly matches with theoretical data. The Infrared data of C=O_ar at 1689.73, C=CHAr_ar at 1639.38, C-N at 1294.15, N-HC-S_ar at 3049.25 etc suggest formation of compound IIIA. The Infrared data of C=O_ar at 1685.52, C=CHAr_ar at 1635.37, C-N at 1319.22, N-HC-S_ar at 3323.12 etc. suggests formation of compound IIIB. In addition, both compounds IIIA and IIIB differ significantly in their melting points (Table 1).

| No | Compound | M.P °C | Elemental Analysis Found(calculated)% | λ_max nm | IR(KBr) cm⁻¹ |
|----|----------|--------|-------------------------------------|----------|-------------|
| 1  | Compound IIIA | 203 | 71.48 (71.2) | 4.12 (4.3) | 3.6 (3.4) | 20.8 (21.1) | 261 | 1689.53(C=O),cyclic 1639.38(C=CHAr) 1294.15(C-N) 3049.25((N-CH-S) |
| 2  | Inclusion complex of compound IIIA with β-cyclodextrin | 212 | - | - | - | - | 259 | 1676.03(C=O),cyclic 1629.74(C=CHAr) 3047.32(N-CH-S) |
| 3  | Compound IIIB | 204 | 71.538 (71.1) | 5.0 (5.13) | 8.07 (7.9) | 15.392 (15.87) | 353 | 1685.52(C=O),cyclic 1635.37(C=CHAr) 1319.22(C-N) 3323.12((N-CH-S) |
| 4  | Inclusion complex of compound IIIB with β-cyclodextrin | 213 | - | - | - | - | 351 | 1668.53 (C=O),cyclic 1627.75(C=CHAr) 1317.22(C-N) 3309.62(N-CH-S) |
The synthesis of inclusion complexes of compounds IIIA and IIIB have been confirmed from melting point data and spectral characteristics (UV-Vis and IR) (Table 1). The melting point of IIIA and its inclusion complex are $203^\circ C$ and $212^\circ C$ respectively. The melting point of IIIB and its inclusion complex are $204^\circ C$ and $214^\circ C$ respectively. A higher melting point of inclusion complexes than their compounds (IIIA and IIIB) are due to the fact that extra amount of thermal energy is required for the compound to be brought out of $\beta$-CD cavity.

The drug recipient interactions are better identified by employing UV and IR spectrophotometry as useful tool. The absorption maxima are shown to undergo a distinct blue shift of 2 nm after their inclusion complex formation with $\beta$-CD (Table 1, Figure 1.1, Figure 1.2). These observations clearly demonstrate transference of the compound from a more protic environment to a less protic environment (cavity of $\beta$-CD). The compound and $\beta$-CD interaction leading to inclusion complex formation is further supported by IR data (Table 1). It is seen that the IR stretching frequencies due to different bonds C=O, N-H, C=CHAr etc. in case compound IIIA and IIIB undergo a downward shift towards lower energy and the peaks become broader, weaker and smoother. Such changes in IR spectral characteristics due to the inclusion complex formation may be attributed to development of weak interactions like H-bonding, van der Waals forces and hydrophobic interactions between host and guest molecules.

![Figure 1.1](image.png)

**Figure 1.1.** Comparison of UV spectra of IIIA (lower curve) and its inclusion complex (upper curve)

The phase solubility plots of IIIA and IIIB in a solution of $\beta$-CD is shown in the Figure 2. In both the cases, it is seen that there is a linear increase in solubility of the compounds with increasing concentration of $\beta$-CD. At a higher concentration of $\beta$-CD, a small negative deviation is observed. Since the slopes of plots are less than unity, the stoichiometry of the inclusion complexes is 1:1.
A Comparative Study of the Inclusion Complexes

Figure 1.2. Comparison of UV spectra IIIB (lower curve) and its inclusion complex (upper curve)

Figure 2. Phase solubility plot of compound IIIA and IIIB

The thermodynamic stability constants ($K_T$) of inclusion complexes are determined by following Benesi-Hilderbrand reaction:

$$\frac{1}{\Delta A} = \frac{1}{\Delta \varepsilon} + \frac{1}{K_{[\text{guest}]_0 \Delta \varepsilon}} \cdot \frac{1}{[\beta-\text{CD}]_0}$$

Where $\Delta A$ is change in absorbance, $[\text{guest}]_0$ is concentration of compound in inclusion complex and $[\beta-\text{CD}]_0$ is molar concentration of $\beta$-CD

A good linear correlation (Figure 3) is obtained for a plot of $1/\Delta A$ verses $1/[\beta-\text{CD}]_0$ for compounds IIIA and IIIB. The values of $K_T$ for the complexes are calculated using the relation: $K_T = \text{Intercept/Slope}$
The $K_T$ values for the inclusion complexes of IIIA and IIIB with β-CD are found to be 522.42 M$^{-1}$ and 390.5 M$^{-1}$ respectively. Lower value $K_T$ for inclusion complex of IIIB than that of IIIA clearly indicates that the stability of inclusion complex of IIIA is more than that of IIIB. Further the data obtained are with in 100 to 1000 M$^{-1}$ (ideal values) indicating appreciable stability for the inclusion complexes.$^{27}$

The thermodynamic parameters associated with encapsulation of compounds IIIA and IIIB with β-CD for 1:1 stoichiometries have been calculated by determining the $K$ values at different temperatures. The $K$ values are found to decrease with increasing temperature (deencapsulation) as expected for an exothermic process.$^{28,29}$ The plot of $\ln K$ as a function of inverse absolute temperature produced a linear plot (Figure 4). In such a case, the slope corresponds to $(-\Delta H/ R)$. From these values and the value of $K_T$ at 298 K, $\Delta G$, $\Delta H$, and $\Delta S$ have been calculated (Table 2).

![Figure 4. Plot of ln K vs. 1/Temperature of compound IIIA and IIIB](image)

Table 2. Thermodynamical data of inclusion complex of compound (IIIA and IIIB) at 298 K

| No | Compound                                      | $K$, M$^{-1}$ | $\Delta G$, kJ/mol | $\Delta H$, kJ/mol | $\Delta S$, kJ/mol |
|----|-----------------------------------------------|---------------|---------------------|---------------------|---------------------|
| 1  | Inclusion complex of IIIA with β-cyclodextrin | 522.42        | -15.5086            | -0.725              | 0.05199             |
| 2  | Inclusion complex IIIB with β-cyclodextrin     | 396.5         | -14.84              | -0.725              | -0.00025            |

As can be seen from the table, $\Delta G$ values are negative for both the complexes. The data clearly demonstrates spontaneous formation of both the inclusion complexes. Secondly a negative value of $\Delta H$ and a positive value of $\Delta S$ at 298 K for compound IIIA suggest the complex formation to be an exothermic and enthalpy controlled process which may be due to the stabilization of compound with in the cavity of β-CD by weak intermolecular forces as suggested earlier.$^{30-32}$ In case of inclusion complex of IIIB, both $\Delta H$ and $\Delta S$ are negative which indicate the complex formation is energetically allowed but entropy forbidden. The negative value of entropy change may be due to steric hindrance with in β-CD cavity which may be correlated with its lower value of stability constant (Table 2).

The data obtained from antibacterial and antifungal studies of compounds IIIA and IIIB suggest that both the antibacterial ($E. coli$) and antifungal activities ($P. notatum$) increase significantly after the formation of inclusion complexes (Table 3). This may be
attributed to enhanced solubility of the drug. As the solubility increases, the drug becomes more bioaccessible to specific tissues leading to increased drug activity.

**Table 3.** Pharmacological data of compound (III\text{A} and III\text{B}) and their inclusion complex and their inclusion complex with β-cyclodextrin

| No | Compound | Conc. (µgm/mL) | Antibacterial activity, Zone of Inhibition of E.Coli (Diameter), mm | Antifungal activity, Zone of Inhibition of Pencilinium Notatum (Diameter), mm |
|----|----------|----------------|---------------------------------------------------------------|---------------------------------------------------------------------|
| 1  | Compound III\text{A} | 0.05           | 9                                                             | 7                                                                   |
| 2  | Inclusion complex of compound III\text{A} With β-cyclodextrin | 0.05           | 12                                                            | 14                                                                  |
| 3  | Compound III\text{B} | 0.05           | 10                                                            | 11                                                                  |
| 4  | Inclusion complex of compound III\text{B} with β-cyclodextrin | 0.05           | 13                                                            | 19                                                                  |

**Conclusion**

From the above results and discussions, it is clear that the solubility of compound III\text{A} and III\text{B} can be improved by inclusion complex formation with β-CD which is a very good analytical tool for enhancing the bioavailability of drugs. Further the study furnishes information about the participation of non-covalent intermolecular forces in between the guest (drug) and host β-cyclodextrin.

**Acknowledgement**

The authors acknowledge the Principal, Institute of Pharmacy and Technology, Salepur (Orissa) for providing laboratory facilities.

**References**

1. Bhatt S S, Shah B R, Trivedi P B, Undavia N K and Desai N C, *Indian J Chem.*, 1994, **33B**, 189.
2. Nask B D and Desai K R, *Asian J Chem.*, 2004, **16**, 1749.
3. Yadav R, Srivastava S, Srivastava S K and Srivastava S D, *Chem An Indian J.*, 2003, **1**, 95.
4. Kumar Vinod and Dhakarey R, *J Indian Council Chem.*, 2003, **46**, 20.
5. Warad D U, Satish C D, Kulkarni V H and Bajgur C S, *Indian J Chem.*, 2000, **39B**, 415.
6. Lodhi R S and Srivastava S D, *Indian J Chem.*, 1998, **37B**, 899.
7. Srivastava S K, Srivastava S and Srivastava S D, *Indian J Chem.*, 1999, **38B**, 183.
8. Panday V K, Gupta V D, Upadhyay M and Singh V K, *Indian J Chem.*, 2004, **44B**, 158.
9. Srivastava S K, Yadav R and Srivastava S D, *Indian J Chem.*, 2004, **43B**, 399.
10. Giri S and Khan M, *J Indian Chem Soc.*, 1994, **71**, 201.
11. Guru S, Yadav R, Srivastava S, Srivastava S K and Srivastava S D, J Indian Chem Soc., 2006, **83**, 1236.
12. Khan M A J A and Shafi S S, *Asian J Chem.*, 2003, **15**, 1443.
13. Mistry K and Desai K R, *E- J Chem.*, 2004, **1(4)**, 189.
14. Purohit M and Srivastava S K, *Indian J Pharma Sci.*, 1992, **54**, 25.
15. Nayak S S, Panda S, Panda P M and Padhy S, *Bul Chem Com.*, 2010, **42(2)**, 147.
1037 S. PANDA et al.

16. Mistry K and Desai K R, Indian J Chem., 2006, 45B, 1762.
17. Pose-Vilarnovo B, Perdomo-Lopez I and Echezarreta-Lopez M, J Pharma Sci., 2001, 13(3), 325.
18. Belikov V G and Kompantseva E V, Khim-Farm.Z., 1990, 24(7), 19.
19. Higuchi T and Connors K A, Adv Anal Chem Instrum., 1965, 4, 117.
20. Benesi H A and Hildebrand J H, J Am Chem Soc., 1999, 71, 2703.
21. Cappuccino J G., Sherman Microbiology: A Laboratory manual, 4th Ed., Addison Wesley Longman, Inc, Tokyo, 329, 1999.
22. Morley D C, J Phathol Bacteriol., 1945, 157, 379.
23. Cooper K E, Nature, 1955, 176, 510.
24. Mohamed K G and Moji C A, Pharm Dev Tech., 2001, 6, 315.
25. Chen Q and Guowang D, Chem J L, 2004, 6(5), 37.
26. Mukna A P and Nagarsenkar M S, AAPS Pharm Sci Tech.,, 2004, 5(1),19.
27. Szetli Z, Molecular entrapment and release properties of drugs by Cyclodextrin, Controlled Drug Bioavailability, Wiley Interscience Publications, 1985, 3, 365.
28. Tommasini S, Raneri D, Ficarra R, Calabro M L and Stancanelli R, J Pharm Biomed Anal., 2004, 35, 379.
29. Rajweski R A and Stella V J, J Pharm Sci., 1996, 85, 1142.
30. Loukas Y L, Vraka V and Gregoridias G, J Pharm Biomed Anal., 1997, 16, 263.
31. Mukna A P and Nagarsenkar M S, AAPS Pharm Sci Tech., 2004, 5(1),19.
32. Nayak S S and Panda S, Res J Chem Environ., 2010, 13(2), 57.
33. Srivastava S D and Shukla D K, ChemInfom, 2008, 39(44),1.
Submit your manuscripts at
http://www.hindawi.com